246 related articles for article (PubMed ID: 10140526)
1. Antibiotic utilization and cost analysis in hospitalized patients with community-acquired pneumonia.
Stein GE; Mantz SL
Hosp Pharm; 1995 Feb; 30(2):132-4, 137. PubMed ID: 10140526
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis.
Marras TK; Nopmaneejumruslers C; Chan CK
Am J Med; 2004 Mar; 116(6):385-93. PubMed ID: 15006587
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community -acquired pneumonia in children.
Aurangzeb B; Hameed A
J Coll Physicians Surg Pak; 2003 Dec; 13(12):704-7. PubMed ID: 15569557
[TBL] [Abstract][Full Text] [Related]
4. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection.
Quenzer RW; Pettit KG; Arnold RJ; Kaniecki DJ
Am J Manag Care; 1997 Jul; 3(7):1027-36. PubMed ID: 10173367
[TBL] [Abstract][Full Text] [Related]
6. [A pharmacoeconomic study of in-hospital treatment against community-acquired pneumonia].
Bermejo Vicedo T; Torralba Arranz A; Hidalgo Correas FJ; Millán Santos I; Rodríguez Morradan B
Farm Hosp; 2004; 28(1):29-35. PubMed ID: 15012176
[TBL] [Abstract][Full Text] [Related]
7. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.
Houck PM; Bratzler DW; Nsa W; Ma A; Bartlett JG
Arch Intern Med; 2004 Mar; 164(6):637-44. PubMed ID: 15037492
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Martin M; Moore L; Quilici S; Decramer M; Simoens S
Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
[TBL] [Abstract][Full Text] [Related]
10. Cost of care for inpatients with community-acquired intra-abdominal infections.
Cattan P; Yin DD; Sarfati E; Lyu R; De Zelicourt M; Fagnani F
Eur J Clin Microbiol Infect Dis; 2002 Nov; 21(11):787-93. PubMed ID: 12461588
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia.
Bhavnani SM; Ambrose PG
Diagn Microbiol Infect Dis; 2008 Jan; 60(1):59-64. PubMed ID: 17889491
[TBL] [Abstract][Full Text] [Related]
12. Continuity of antibiotic therapy in patients admitted from the emergency department.
Shah MN; Schmit J; Croley WC; Meltzer D
Ann Emerg Med; 2003 Jul; 42(1):117-23. PubMed ID: 12827131
[TBL] [Abstract][Full Text] [Related]
13. Management of community-acquired pneumonia by trained family general practitioners.
Potena A; Simoni M; Cellini M; Cartabellotta A; Ballerin L; Piattella M; Putinati S
Int J Tuberc Lung Dis; 2008 Jan; 12(1):19-25. PubMed ID: 18173872
[TBL] [Abstract][Full Text] [Related]
14. Blood cultures do not change management in hospitalized patients with community-acquired pneumonia.
Ramanujam P; Rathlev NK
Acad Emerg Med; 2006 Jul; 13(7):740-5. PubMed ID: 16766742
[TBL] [Abstract][Full Text] [Related]
15. Costs of treating lower respiratory tract infections.
Monte SV; Paolini NM; Slazak EM; Schentag JJ; Paladino JA
Am J Manag Care; 2008 Apr; 14(4):190-6. PubMed ID: 18402511
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of clarithromycin in the treatment of community-acquired pneumonia].
Parola D; Dell'Orso D; Terzano C
Recenti Prog Med; 2000 Jan; 91(1):12-5. PubMed ID: 10705778
[TBL] [Abstract][Full Text] [Related]
17. Treatment and outcomes of community-acquired pneumonia at Canadian hospitals.
Feagan BG; Marrie TJ; Lau CY; Wheeler SL; Wong CJ; Vandervoort MK
CMAJ; 2000 May; 162(10):1415-20. PubMed ID: 10834044
[TBL] [Abstract][Full Text] [Related]
18. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center.
Gauthier M; Chevalier I; Sterescu A; Bergeron S; Brunet S; Taddeo D
Pediatrics; 2004 Oct; 114(4):e469-76. PubMed ID: 15466073
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB).
Lavoie F; Blais L; Castilloux AM; Scalera A; LeLorier J
Can J Clin Pharmacol; 2005; 12(2):e212-7. PubMed ID: 15998960
[TBL] [Abstract][Full Text] [Related]
20. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
